Advances in Imaging for Diagnosis of Alzheimer Disease
May 1st 2005Often, a clinical diagnosis of AD comes too late for an individual to benefit from treatment. Clinicians can assign the diagnosis of mild cognitive impairment (MCI) to patients with memory complaints, but they cannot state emphatically which of these individuals will progress to AD. Typically, about 10% to 15% of persons diagnosed with MCI convert to AD within a year, while 30% to 40% do not convert--at least not for another 6 to 8 years.
Neurologists Urged to Clear the Air
May 1st 2005Joseph I. Sirven, MD, and Joseph F. Drazkowski, MD, neurologists at the Mayo Clinic in Phoenix, led a recent study in partnership with the Walter Cronkite School of Journalism and Mass Communication at Arizona State University (ASU) to determine how well medical risks and treatment advances for neurologic conditions are conveyed in US newspaper articles.1 Their findings reveal that coverage of neurologic disorders does not always correlate with the prevalence of the disorders and that more collaboration is needed between journalists and neurologists to better educate the public.
Drug Safety Oversight: Before and After FDA Approval
April 10th 2005Congress and the Bush Administration are wrangling over how to strengthen the drug safety oversight activities at the FDA in the wake of the recent controversies over cyclooxygenase-2 inhibitors and pediatric antidepressants. The White House intends to create an independent Drug Safety Oversight Board (DSB) within the FDA. Several key senators like the idea but insist that the DSB be separate from the FDA to keep it from being "under the thumb" of that agency.
Research Results Stress Need for Assessing Outcomes After Spinal Surgery
April 10th 2005Research presented in late February at the annual meeting of the American Academy of Orthopaedic Surgeons underscores the increasing importance of functional assessment tools to quantify outcomes after spinal intervention, whether in measuring the effectiveness of a specific procedure or in better understanding the risks faced by patients who undergo spinal surgery in general.
Strategies for Treating Osteoporosis and Its Neurologic Complications
April 10th 2005Osteoporosis is a disorder characterized by low bone mass and microarchitectural deterioration with resulting compromised bone strength and increased risk of fracture.1 The World Health Organization defines osteoporosis based on T-scores, which reflect bone mineral density (BMD) relative to mean BMD for healthy 25-year-old same-sex populations. A T-score between 0 and 21 is considered normal density, a score between 21 and 22.5 indicates osteopenia, and a score of less than 22.5 signifies osteoporosis.2 Severe osteoporosis is defined as a T-score of less than 22.5 combined with a fragility fracture.2
West Nile Virus: Researchers Make Inroads Into Diagnosis and Treatments
April 10th 2005Since its 1999 appearance in New York, West Nile virus (WNV) has spread relentlessly westward each year, opening up new fronts in the Midwest and the mountain states until pummeling California in the summer of 2004. The flavivirus, which is spread primarily by mosquitos, affects a variety of animals, including humans, horses, and nearly 300 bird species. As of October 15, 2004, about 940,000 Americans had been infected, of whom 190,000 became ill and 6790 developed WNV's most feared complications: neuroinvasive disease, including meningitis, encephalitis, and acute flaccid paralysis.1
Hope, Then Disappointment, for Multiple Sclerosis Therapy
April 10th 2005When Hillel Panitch, MD, decided last summer to accept an invitation to make a presentation on the status of multiple sclerosis (MS) clinical trials at the annual meeting of the American Society for NeuroTherapeutics (ASENT), he did not realize just how timely his presentation would be. "This turned out to be a little more topical than I thought it would be, because of the news over the last few days," he told attendees of the session on March 4 in Washington, DC. "The news," of course, was the withdrawal from the market of natalizumab (Tysabri, Elan Corporation/Biogen Idec), a newly approved drug for MS, and the discontinuation of clinical trials after 1 fatality and an occurrence of another serious disorder in one of the trials.
Parkinson Disease: The Ups and Downs of Developing Therapies
April 10th 2005Levodopa (l-dopa) and dopamine agonists are the main treatment for Parkinson disease (PD), but these therapies are of limited value in the long course of the illness because they counter a neurotransmitter deficit but do not halt neurodegeneration. In this main article and in an accompanying story, we offer an update on the status of Parkinson treatments today.
Virtually Possible: Treating and Preventing Psychiatric Wounds of War
April 2nd 2005With one in six Iraqi War veterans exhibiting mental health problems, psychiatrists are faced with the challenge of reducing or averting the psychological wounds of war and preventing long-term, service-connected disabilities. At the 13th Annual Medicine Meets Virtual Reality Conference, new therapies using virtual reality were put to the test.
Sexual Assault Among Male Veterans
April 2nd 2005Little attention has been paid to the prevalence of sexual assault and its sequelae among military men. The past-year prevalence of sexual assault among enlisted men ranges from 0.4% to 3.7%, a figure equal to or exceeding the lifetime prevalence among civilian men in some studies. Increased awareness and understanding of male sexual assault as well as routine screening of all patients, regardless of gender, for exposure to sexual victimization will enhance their recovery.
Reporting Under Fire: Understanding Psychopathology of War Journalists
April 2nd 2005The dozens of journalists killed while covering the current war in Iraq gives currency to the dangers encountered by those who bring us the news from the world's conflict zones. Despite the risks inherent in their profession, it is only recently that the psychological health of war reporters has been captured in a systematic and empirical manner.
Road Rage: Are Our Patients Driving Angry?
April 1st 2005Road rage is well known in popular culture and to many people it is a common and dangerous experience. Alcohol problems, illicit drug use and general psychiatric distress are associated with road rage perpetration. Road rage incidents may also result in psychiatric distress. Although treatment for road rage has received little research attention, encouraging results have been reported from specialized programs.
Serious Delinquency and Gang Membership
April 1st 2005Youth gangs are a recognized risk factor for adolescent violence and delinquency. This article reviews recent research on these topics, including the prevalence, characteristics and influence of youth gangs, and discusses the implications of those findings for clinical practice.
Psychiatric Aspects of HIV: Optimizing Care for Patients
April 1st 2005Mental illness occurs more frequently among people infected with HIV. In addition, individuals with mental illnesses are at greater risk for contracting HIV. Therefore, psychiatry has a great deal to offer in the management of patients with HIV--whether through proper patient education or safe and effective psychopharmacology.
Improving Quality of Life: Psychiatric Aspects of Treating Prostate Cancer
April 1st 2005Prostate cancer, the second leading cause of cancer death in men, is the most common cancer in males in the United States. Out of an estimated 230,000 new cases in 2004, more than 70% will occur in men over age 65. Close liaison between urologists, prostate oncologists, radiation oncologists and psychiatrists allows for improved information transfer and proper referrals, as well as improved identification of the symptoms as being either physical, psychological or both.
Sweet Sorrow: The Relationship Between Depression and Diabetes Mellitus
April 1st 2005Multiple studies show that diabetes approximately doubles the risk of comorbid depression. Furthermore, major depressive disorder is a risk factor for the subsequent development of type 2 diabetes mellitus. Treatments for depression in the setting of diabetes must be evaluated for their effects on blood glucose levels, propensity for weight gain, possible concomitant use for diabetic neuropathy and potential drug interactions.